Please provide your email address to receive an email when new articles are posted on . An unmet need exists to treat generalized pustular psoriasis and its flares, leading many patients to seek ...

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the relapsing nature of generalized pustular psoriasis and how the difficulty in diagnosing the disease affects outcomes for patients. Ryan ...

Imsidolimab is a humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor. Treatment with imsidolimab led to significant clearance of pustulation, erythema, and scaling in ...

Generalized pustular psoriasis (GPP) is the rarest form of psoriasis, a chronic autoimmune skin condition. Unlike other forms, GPP can be severe or even life-threatening. The disease causes flares of ...

“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...

Please provide your email address to receive an email when new articles are posted on . In this video, Tracey Henslee, CRNP, discusses the treatment of pustular psoriasis, a highlight of this year’s ...

Mark G. Lebwohl, MD, and Maria Lopes, MD, MS, review the incidence and prevalence of generalized pustular psoriasis as well as direct and indirect costs associated with the disease. Ryan Haumschild, ...

An international panel of more than 30 experts has developed a consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP). The new definition, published in JAMA Dermatology, ...

Catching psoriasis early is vital for managing the disease effectively and minimizing its impact on your quality of life. Timely intervention can help slow disease progression, alleviate symptoms, and ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...